Post‐transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high‐risk acute myeloid leukaemia

E-ISSN： 1365-2141|169|5|756-759

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.5, 2015-06, pp. : 756-759

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Maintenance lenalidomide in combination with 5‐azacitidine as post‐remission therapy for acute myeloid leukaemia

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 2, 2015-04 ,pp. : 199-210

John Wiley & Sons Inc

Access to resources Recommend Favorite

Gemtuzumab Ozogamicin (Mylotarg^®) in Children with Refractory or Relapsed Acute Myeloid Leukemia

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 269-272

Karger

Access to resources Recommend Favorite

Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials

Oncology Research and Treatment, Vol. 30, Iss. 12, 2007-11 ,pp. : 657-662

Karger

Access to resources Recommend Favorite

Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients

Acta Haematologica, Vol. 118, Iss. 1, 2007-03 ,pp. : 7-9

Karger

Access to resources Recommend Favorite

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia

CANCER, Vol. 119, Iss. 22, 2013-11 ,pp. : 4036-4043

John Wiley & Sons Inc

Access to resources Recommend Favorite